Trials / Recruiting
RecruitingNCT07399977
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
A Nonrandomized Trial Using DNA Liquid Biopsies to Guide Anticoagulation For Patients With Cancer-Associated Thromboembolism
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 259 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | MSK-ACCESS | MSK-ACCESS is a ctDNA sequencing assay |
| DIAGNOSTIC_TEST | ctDNA/VTE Risk Score: | Machine learning Venous Thromboembolism/VTE risk score mode |
Timeline
- Start date
- 2026-01-30
- Primary completion
- 2030-01-30
- Completion
- 2030-01-30
- First posted
- 2026-02-10
- Last updated
- 2026-02-12
Locations
8 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT07399977. Inclusion in this directory is not an endorsement.